Anti-human matrix metalloproteinase 9 antibody, antibody pair and detection kit
By developing high affinity and high specificity rabbit-derived monoclonal antibody pairs, combined with dual-anti-sandwich method enzyme-linked immunoassay, the problem of insufficient sensitivity and specificity of MMP-9 detection in the prior art was solved, and efficient and accurate Test results provide important tools for disease diagnosis and treatment.
Patent Information
- Application Number
- CN202411211856.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-30
AI Technical Summary
Existing murine monoclonal antibodies used to detect matrix metalloproteinase 9 (MMP-9) have low affinity and specificity, resulting in insufficient detection sensitivity and accuracy, and fewer types of rabbit monoclonal antibodies and their detection kits. , limiting the supply of tools for disease diagnosis and treatment.
A high affinity and high specificity human matrix metalloproteinase 9 rabbit monoclonal antibody and its antibody pair were developed. Through the dual-anti-sandwich method enzyme-linked immunoassay detection system, combining the primary and secondary antibodies, it realizes the human MMP- 9. High sensitivity and good specificity detection.
It improves the sensitivity and specificity of MMP-9 detection, provides accurate and reliable detection results, has the advantages of strong anti-interference ability, strong system stability and wide detection concentration range, and has important scientific research and clinical diagnostic value.
Smart Images

Figure CN119060188A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of monoclonal antibody preparation, and in particular to an anti-human matrix metalloproteinase 9 antibody, an antibody pair and a detection kit. Background Art
[0002] Matrix metalloproteinases (MMPs) are endopeptidases involved in the formation and remodeling of the extracellular matrix. Matrix metalloproteinase-9 (MMP-9) belongs to the gelatinase family of MMPs, also known as gel metalloproteinase B or gelatinase B, which can catalyze the degradation of large extracellular matrix components and certain cell surface proteins. The substrates of MMP-9 include collagen types IV, V, VII, X, and XI, core proteins of proteoglycans, gelatin, fibronectin, laminin, elastin, etc. Cytokines and their receptors are also substrates of MMP-9. MMP-9 is involved in many physiological processes in the human body, such as tissue changes, the release of growth factors and cytokines. MMP-9 can decompose structural complexes in the respiratory tract and lungs, such as ECM and basement membrane, and therefore can participate in the reconstruction of the respiratory tract and lungs. It has a regulatory effect on the activity of other proteases and cytokines, can degrade α1 antitrypsin, protect the activity of neutrophil elastase, and can enhance the collagenolytic activity of collagen cells and MMP-13 in collagen colloids. MMP-9 can also decompose a 62-amino acid peptide from interleukin-8 (IL-8), increasing its chemotactic activity to neutrophils by 10 times, but it also inhibits other neutrophil chemotactic factors. In addition, MMP-9 is involved in many pathological processes. Many studies have shown that MMP-9 promotes the growth of tumor cells by promoting the formation of new blood vessels on the one hand, and promotes the infiltration and invasion of tumor cells to the basement membrane on the other hand by degrading and destroying the basement membrane; MMP-9 can be significantly increased in the tissues of malignant tumors such as colon cancer, gastric cancer, lung cancer and cervical cancer, making it a potential target for anti-tumor drugs. In addition, studies have shown that increased activity of MMP-9 will damage the corneal epithelium and lead to ocular surface barrier dysfunction. The MMP-9 level in patients with moderate to severe dry eye disease is correlated with clinical examination results and is a non-specific inflammatory marker. Therefore, the detection of MMP-9 content plays an important role in the diagnosis, treatment and prognosis of many diseases.
[0003] At present, the qualitative and quantitative analysis of MMP-9 mostly uses immunological methods such as enzyme-linked immunosorbent assay, immunoturbidimetry, immunoprecipitation, and immunofluorescence. The key to establishing the above methods is to prepare specific monoclonal antibodies. The quality of monoclonal antibodies largely determines the sensitivity and accuracy of immunoassay methods. Traditional clinical diagnosis uses mouse monoclonal antibodies, which generally have lower affinity and specificity than rabbit monoclonal antibodies, resulting in poor sensitivity and accuracy in the immunoassay system developed based on mouse monoclonal antibodies. Summary of the invention
[0004] Currently, there are few types of rabbit monoclonal antibodies and detection kits for detecting MMP-9, and there is a lack of diagnostic and therapeutic tools for related diseases. In order to solve or at least partially alleviate the above technical problems, the present application provides a rabbit monoclonal antibody against human matrix metalloproteinase 9 and an antibody pair thereof, the antibody having high affinity and high specificity for human MMP-9, and the human MMP-9 double antibody sandwich enzyme-linked immunosorbent assay system developed using the aforementioned antibody pairing has the advantages of high detection sensitivity, good specificity, strong anti-interference ability, accurate and reliable results, strong system stability and a wide range of detection concentrations. Therefore, the present invention provides the use of the aforementioned antibodies and antibody pairs in the preparation of human MMP-9 detection kits, and provides a detection kit containing the aforementioned antibodies and antibody pairs. The present invention is achieved through the following technical solutions:
[0005] The first aspect of the present invention provides an anti-human matrix metalloproteinase 9 antibody, selected from a first antibody or a second antibody, wherein: the amino acid sequences of CDR1-3 on the light chain variable region of the first antibody are respectively shown as SEQ ID NOs.3-5, and the amino acid sequences of CDR1-3 on the heavy chain variable region are respectively shown as SEQ ID NOs.8-10; the amino acid sequences of CDR1-3 on the light chain variable region of the second antibody are respectively shown as SEQ ID NOs.13-15, and the amino acid sequences of CDR1-3 on the heavy chain variable region are respectively shown as SEQ ID NOs.18-20.
[0006] Furthermore, the amino acid sequence of the light chain variable region of the first antibody is shown as SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.7; the amino acid sequence of the light chain variable region of the second antibody is shown as SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.17.
[0007] Furthermore, the amino acid sequence of the light chain of the first antibody is shown as SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown as SEQ ID NO.6; the amino acid sequence of the light chain of the second antibody is shown as SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown as SEQ ID NO.16.
[0008] Furthermore, the first antibody and / or the second antibody is a full-length antibody or an antigen-binding region of the full-length antibody; the antigen-binding region is selected from Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv or sc(Fv)2.
[0009] The second aspect of the present invention provides an anti-human matrix metalloproteinase-9 antibody pair, which consists of the first antibody and the second antibody as described above.
[0010] The third aspect of the present invention provides the use of the anti-human matrix metalloproteinase-9 antibody or antibody pair described above in the preparation of a human matrix metalloproteinase-9 detection kit.
[0011] The fourth aspect of the present invention provides a human matrix metalloproteinase 9 detection kit, comprising the first antibody and / or the second antibody as described above.
[0012] Furthermore, the detection kit is an enzyme-linked immunosorbent assay kit, an enzyme-linked immunospot assay kit, an immunohistochemistry kit, an immunofluorescence assay kit, an immunoblotting kit or a flow cytometry kit.
[0013] Furthermore, the detection kit is a double antibody sandwich enzyme-linked immunosorbent assay kit, comprising a first antibody and a second antibody, wherein the first antibody serves as a capture antibody, the second antibody serves as a detection antibody, and the second antibody is connected to a detection label.
[0014] The fifth aspect of the present invention provides a nucleic acid molecule, a recombinant vector comprising the nucleic acid molecule or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule encodes the first antibody or the second antibody as described above.
[0015] Compared with the prior art, the advantages and positive effects of the present invention are:
[0016] The two antibodies provided by the present invention have high affinity and high specificity for human matrix metalloproteinase 9 (MMP-9), and the affinity constants are 0.432nM and 0.897nM respectively. The antibodies specifically recognize and bind to human MMP-9, and have no cross-reaction with similar proteins. The human MMP-9 double antibody sandwich enzyme-linked immunosorbent assay system developed using the above two antibodies has the advantages of high detection sensitivity, good specificity, strong anti-interference ability, accurate and reliable results, strong system stability and wide detection concentration range, and has important scientific research and practical value for the detection of human MMP-9 in the industry and the diagnosis and treatment of related diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments.
[0018] Figure 1 The vector map used to construct the rabbit monoclonal antibody expression vector in Example 1 of the present invention, from left to right are the pBR322 vector maps carrying the light chain constant region and the heavy chain constant region;
[0019] Figure 2 This is an affinity curve diagram of the binding of monoclonal antibody 3F5 to human MMP-9 protein in Example 2 of the present invention;
[0020] Figure 3 This is an affinity curve diagram of the binding of monoclonal antibody 3G3 to human MMP-9 protein in Example 2 of the present invention;
[0021] Figure 4 The standard curve for detecting human MMP-9 protein using a double antibody sandwich ELISA system based on monoclonal antibodies 3F5 and 3G3 established in Example 3 of the present invention;
[0022] Figure 5 This is a graph showing the specificity determination results of the double antibody sandwich ELISA system established based on monoclonal antibodies 3F5 and 3G3 in Example 4 of the present invention;
[0023] Figure 6 This is a graph showing the results of thermal stability determination of a double antibody sandwich ELISA system established based on monoclonal antibodies 3F5 and 3G3 in Example 5 of the present invention. DETAILED DESCRIPTION
[0024] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0025] Based on the information contained in the present invention, it is easy for those skilled in the art to make various changes to the precise description of the present invention without departing from the spirit and scope of the appended claims. It should be understood that the scope of the present invention is not limited to the defined processes, properties or components, because these embodiments and other descriptions are only for the purpose of illustrating specific aspects of the present invention. In fact, various changes that a person skilled in the art or related fields can obviously make to the embodiments of the present invention are covered within the scope of the appended claims.
[0026] In order to better understand the present invention but not to limit the scope of the present invention, all the numbers and other numerical values used in the present invention to express the amount, percentage, etc. should be understood as modified by the word "about" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the appended claims are approximate values, which may be changed according to the different ideal properties to be obtained. Each numerical parameter should at least be regarded as obtained according to the reported significant figures and by conventional rounding methods.
[0027] In addition, it should be noted that, unless otherwise defined, in the context of the present invention, the scientific and technical terms used should have the meanings commonly understood by those of ordinary skill in the art.
[0028] The meaning of the terms "including", "comprising", "containing", "having" and the like is non-restrictive, that is, other steps and other ingredients that do not affect the results can be added. The term "and / or" should be regarded as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" is regarded as including the following situations: (i) A, (ii) B and (iii) A and B. The terms "first", "second", etc. are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that such usage can be interchangeable under appropriate circumstances.
[0029] The terms "rabbit monoclonal antibody", "monoclonal antibody", "rabbit antibody" and "rabbit monoclonal antibody" and other similar terms have the same meaning. Unless otherwise specified, they all refer to antibodies that specifically bind to human matrix metalloproteinase-9 (MMP-9). The modifier "rabbit" indicates that the complementary determining region (CDR) of the antibody is derived from a rabbit immunoglobulin sequence. The terms "human matrix metalloproteinase 9", "human MMP-9", "Human MMP-9", "HumanMMP9" and other similar terms have the same meaning.
[0030] An antibody is an immunoglobulin molecule that can specifically bind to a target antigen or epitope through at least one antigen recognition site located in the variable region of the immunoglobulin molecule. In the present invention, the term "antibody" should be interpreted in the broadest sense and includes different antibody structures, including but not limited to so-called full-length antibodies, antibody fragments, and their genetic or chemical modifications, as long as they exhibit the desired antigen-binding activity.
[0031] A typical antibody molecule (full-length antibody) consists of two identical light chains (L) and two identical heavy chains (H). Light chains can be divided into two types, namely κ chain and λ chain; heavy chains can be classified into five types, namely μ, δ, γ, α and ε chains, and antibodies are defined as IgM, IgD, IgG, IgA and IgE, respectively. The amino acid sequences near the N-terminus of the heavy and light chains vary greatly, while the amino acid sequences of other parts are relatively constant. The regions near the N-terminus of the light and heavy chains where the amino acid sequences vary greatly are called variable regions (V), and the regions near the C-terminus where the amino acid sequences are relatively stable are called constant regions (C). The heavy chain variable region (VH) and the light chain variable region (VL) are usually the most variable parts of the antibody and contain antigen recognition sites. The VH and VL regions can be further subdivided into hypervariable regions (HVR) and framework regions (FR). The hypervariable regions are also called complementarity determining regions (CDRs), which are ring-shaped structures. The heavy chain CDR and the light chain CDR are closely together and cooperate with each other through the FR region, forming a surface that can complement the three-dimensional structure of the target antigen or epitope, which determines the specificity of the antibody and is the site where the antibody recognizes and binds to the antigen. The FR region is the more conservative part of VH and VL. They are generally in a β-folded configuration and are connected by three CDRs that form a connecting loop. Each VH and VL is usually composed of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0032] CDRs and FRs can be identified according to the Kabat definition, the Chothia definition, the accumulation of both the Kabat definition and the Chothia definition, the AbM definition, the contact definition, the IMGT unique numbering definition and / or the conformational definition, or any CDR determination method known in the art. As used herein, the Kabat numbering system is used to define.
[0033] The light chain constant region (CL) and the heavy chain constant region (CH) are not directly involved in the binding of antibodies to antigens, but they exhibit different effector functions, such as participating in antibody-dependent cytotoxicity of antibodies. The length of CL of different types of Ig (κ or λ) is basically the same, but the length of CH of different classes of Ig is different, such as IgG, IgA and IgD include CH1, CH2 and CH3, while IgM and IgE include CH1, CH2, CH3 and CH4. The amino acid sequences of the heavy chain and light chain constant regions of antibodies are well known in the art.
[0034] A full-length antibody is the most complete antibody molecular structure and has a typical Y-shaped molecular structure. Therefore, in the context of the present invention, "full-length antibody", "complete antibody" and "Y-shaped antibody" have the same meaning and can be used interchangeably.
[0035] Antibody fragments are one or more parts or fragments of a full-length antibody, which substantially retain the same biological function or activity as the full-length form. Specifically, antibody fragments at least include the same CDR region as the full-length antibody, and more preferably have the same variable region, thereby retaining complete antigen recognition and binding sites, and can bind to the same antigen as the full-length antibody, especially to the same epitope. In typical examples, antibody fragments include: Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv, sc(Fv)2, and these antibody fragments can be obtained by conventional techniques in the art.
[0036] (i) Fab: Antigen-binding fragment (Fab) is a monovalent fragment consisting of a complete light chain (variable region and constant region) and a part of the heavy chain (variable region and the first constant region). By proteolytic cleavage of the full-length antibody, fragments such as Fab, F(ab')2, and Fab' can be obtained. For example, under the action of papain, IgG can be degraded into two Fab fragments and one Fc fragment; under the action of pepsin, IgG can be degraded into one F(ab')2 fragment and one pFc' fragment. The F(ab')2 fragment is further reduced to form two Fab' fragments. Since Fab has an antigen-binding region and a part of the constant region, it not only has the same antibody-antigen affinity and excellent tissue penetration as scFv, but also has a more stable structure.
[0037] (ii) F(ab)2: A bivalent fragment consisting of two Fabs linked by a disulfide bridge at the hinge region.
[0038] (iii) Fv: The variable fragment (Fv) is located at the N-terminus of the antibody Fab fragment, contains only the variable region, and is composed of the variable regions of a light chain and a heavy chain. It is a dimer of VH and VL non-covalently bound (VH-VL dimer). The three CDRs of each variable region interact with each other to form an antigen binding site on the surface of the VH-VL dimer, which has the ability to recognize and bind to antigens, although the affinity is lower than that of the intact antibody.
[0039] (iv) (Fv)2: consists of two Fv fragments covalently linked together.
[0040] (v) scFv: Single-chain variable fragment (scFv) is an Fv fragment composed of a single polypeptide chain, which is composed of a heavy chain variable region (VH) and a light chain variable region (VL) connected by a flexible linker (generally composed of 10-25 amino acids), which retains the binding specificity of the original antibody to the antigen. The linker in the present invention is not particularly limited as long as it does not hinder the expression of the antibody variable regions connected to its two ends. Compared with full-length antibodies, scFv has the characteristics of small molecular weight, so it has higher penetration and lower immune side effects.
[0041] (vi) The sc(Fv)2 fragment is composed of two heavy chain variable regions and two light chain variable regions connected via a linker or the like.
[0042] The terms "monoclonal antibody" or "single antibody" and the like are used interchangeably and refer to a homogeneous antibody population, i.e., the individual antibodies constituting the population are identical except for a small amount of mutations and / or post-translational modifications (e.g., isomerization, amidation) that may occur naturally. "Monoclonal antibodies" are highly specific and exhibit a single binding specificity and affinity for the same or substantially identical epitopes on an antigen. The modifier "monoclonal" indicates that the antibody is obtained from a substantially homogeneous antibody population and should not be construed as limiting the source or preparation method of the antibody. The antibody can be prepared by a variety of methods, including but not limited to hybridoma methods, phage display methods, yeast display methods, recombinant DNA methods, single cell screening, or single cell sequencing methods.
[0043] The term "specific binding" is a well-known term in the art, and a molecule exhibits "specific binding" if it reacts with a specific target antigen or epitope more frequently, more rapidly, longer lastingly, and / or with greater affinity than with other target antigens or epitopes. "Specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding.
[0044] In order to make the above-mentioned objects and advantages of the present invention more obvious and understandable, the specific implementation methods of the present invention are described in detail below.
[0045] The present invention has successfully developed two high-affinity rabbit monoclonal antibodies against human matrix metalloproteinase-9 (MMP-9), with affinity constants K DThe concentrations of the antibodies are 0.432nM and 0.897nM, respectively. The antibodies have high specificity and good thermal stability. They specifically recognize and bind to human MMP-9 and have no cross-reaction with similar proteins. The protein interaction non-standard technology verifies that the antibodies bind to different antigenic determinants on the surface of the human MMP-9 protein, and can be used as paired antibodies to establish a double antibody sandwich ELISA method for human MMP-9. One of the strains is used as a capture antibody to coat the microplate to make a solid-phase antibody, and then the MMP-9 antigen is added. Then, the other strain is used as a detection antibody to label biotin to form a double antibody sandwich (capture antibody-antigen-biotinylated detection antibody) ELISA detection system. After being treated with streptavidin-labeled avidin, the substrate TMB is added for color development, and the human MMP-9 content can be quantitatively detected. The detection limit is as low as 11.53pg / mL. It has the advantages of high detection sensitivity, good specificity, strong anti-interference ability, accurate and reliable results, strong system stability and a wide detection concentration range, and is of great significance in clinical diagnosis and scientific research applications.
[0046] Based on this, an embodiment of the present invention provides an anti-human matrix metalloproteinase 9 antibody, which is selected from a first antibody or a second antibody, wherein the first antibody and the second antibody both include a light chain variable region and a heavy chain variable region, and the light chain variable region and the heavy chain variable region both include three complementary determining regions (CDRs), which are named CDR1, CDR2 and CDR3, respectively; wherein: the amino acid sequences of CDR1, CDR2 and CDR3 on the light chain variable region of the first antibody are shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively; the amino acid sequences of CDR1, CDR2 and CDR3 on the light chain variable region of the second antibody are shown as SEQ ID NO.13, SEQ ID NO.14 and SEQ ID NO.15, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.20, respectively. Shown in NO.20.
[0047] The antibody containing the above CDR sequence prepared by the present invention has high affinity and high specificity for human matrix metalloproteinase 9 (MMP-9), provides an antibody material with excellent performance for qualitatively or quantitatively detecting the level of human MMP-9 by immunological means, and is beneficial to significantly improve the accuracy, specificity, sensitivity, stability and reliability of immunoassay results.
[0048] Optionally, the light chain variable region and the heavy chain variable region each include 4 framework regions (FRs), and the 4 FRs and 3 CDRs are arranged alternately in sequence to form a variable region. The amino acid sequence of the light chain variable region (VL) of the first antibody is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region (VH) is shown in SEQ ID NO.7. The amino acid sequence of the light chain variable region (VL) of the second antibody is shown in SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region (VH) is shown in SEQ ID NO.17.
[0049] Optionally, the first antibody and the second antibody further comprise a light chain constant region (CL) and a heavy chain constant region (CH), wherein the CL and VL of each antibody constitute a light chain (FL), and the CH and VH constitute a heavy chain (FH). The constant region of an antibody can usually be obtained through public inquiries, such as searching for rabbit IgG gamma C reign to obtain CH, and searching for rabbit IgG Kappa C reign to obtain CL through the IMGT online database (www.imgt.org).
[0050] Specifically, the amino acid sequence of the light chain of the first antibody is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.6. The amino acid sequence of the light chain of the second antibody is shown in SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.16.
[0051] Optionally, the first antibody and / or the second antibody is a full-length antibody (having a typical Y-shaped molecular structure) or an antigen binding region of the full-length antibody; the antigen binding region refers to a polypeptide that substantially maintains the same biological function or activity as the full-length form of a rabbit monoclonal antibody. Specifically, the antigen binding region includes the CDR region as described above, and more preferably has the variable region as described above, thereby retaining a complete antigen recognition and binding site, and can bind to the same antigen as the full-length antibody, especially to the same epitope. Optionally, the antigen binding region is selected from at least one of Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv and sc(Fv)2. These antigen binding regions can be obtained by conventional techniques in the art.
[0052] Based on this, another embodiment of the present invention provides an anti-human matrix metalloproteinase-9 antibody pair, which consists of the first antibody and the second antibody as described above.
[0053] The first antibody and the second antibody of the present invention bind to different antigenic epitopes of human MMP-9 and can be used as paired antibodies for a double antibody sandwich enzyme-linked immunosorbent assay (ELISA) detection system. The double antibody sandwich ELISA system is constructed with the first antibody as a capture antibody and the second antibody as a detection antibody. The system has the advantages of high detection sensitivity, good specificity, strong anti-interference ability, accurate and reliable results, strong system stability, and a wide detection concentration range. The minimum detection limit is effectively improved, and the detection concentration can be as low as 11.53 pg / mL, providing an effective detection means for high-precision detection of trace levels of human MMP-9 protein in biological samples.
[0054] Based on the same inventive concept as above, another embodiment of the present invention provides the use of the anti-human matrix metalloproteinase-9 antibody or antibody pair as described above in the preparation of a human matrix metalloproteinase-9 detection kit.
[0055] The advantages of using the anti-human MMP-9 antibody or antibody pair in preparing a human MMP-9 detection kit are the same as the advantages of the anti-human MMP-9 antibody or antibody pair over the prior art as described above, and will not be repeated here.
[0056] Based on the same inventive concept as above, another embodiment of the present invention provides a human matrix metalloproteinase 9 detection kit, wherein the detection kit comprises the first antibody and / or the second antibody as described above.
[0057] It should be emphasized that the first antibody and the second antibody can be used separately, together, or in pairs. When detecting, if used separately or together, the first antibody and / or the second antibody is used as a primary antibody or a capture antibody, the sample to be tested is contacted with the first antibody and / or the second antibody, and then the antibody is detected. In some embodiments, the first antibody and / or the second antibody can be connected (covalently or non-covalently) to a detection label, and the qualitative or quantitative detection of MMP-9 is achieved by analyzing the change in the identifiable signal generated by the detection label. In other embodiments, the anti-human MMP-9 antibody (as a primary antibody or a capture antibody) is not labeled, and the detection label is connected to a secondary antibody (as a detection antibody) or other molecules that can bind to the primary antibody. For example, if the anti-human MMP-9 antibody is a rabbit IgG antibody, then the secondary antibody can be an anti-rabbit IgG antibody, thereby generating a change in the identifiable signal through the secondary antibody connected to the detection label. When used in pairs, one of the first antibody and the second antibody is used as a primary antibody or a capture antibody, and the other is used as a secondary antibody or a detection antibody.
[0058] The above-mentioned detection method adopts common immunological methods, including but not limited to: enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot assay (ELISPOT), immunohistochemistry (IHC), immunofluorescence (IF), immunoblotting (WB), flow cytometry (FC), etc. The detection objects include recombinantly expressed MMP-9 protein, cell-secreted MMP-9 protein or MMP-9 protein in human serum and plasma. The detection samples include but are not limited to serum, plasma, urine, cell culture fluid and tissue homogenate.
[0059] Preferably, the detection kit is a double antibody sandwich enzyme-linked immunosorbent assay kit, comprising a first antibody and a second antibody, wherein the first antibody serves as a capture antibody (or primary antibody), and the second antibody connected with a detection marker serves as a detection antibody (or secondary antibody).
[0060] The above-mentioned detection labels for generating identifiable signal changes include, but are not limited to: biotin, fluorescent dyes (such as umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride), fluorescent proteins (such as allophycocyanin, phycoerythrin, PerCP and phycocyanin), enzymes (such as alkaline phosphatase, acid phosphatase, β-galactosidase, glucose oxidase, horseradish peroxidase, acetylcholinesterase, avidin), colloidal gold, colored magnetic beads, latex particles, radionuclides, detection antibodies or combinations thereof.
[0061] The examples of the present application also disclose a preferred method for preparing the above-mentioned anti-human matrix metalloproteinase-9 antibody, which is obtained by genetic engineering recombination technology; specifically, a DNA molecule encoding the heavy chain and light chain genes of the antibody of the present application is obtained by chemical synthesis or PCR amplification, the obtained DNA molecule is inserted into an expression vector, and then transfected into a host cell, and the transfected host cell is cultured under appropriate conditions to express the antibody of the present invention.
[0062] Based on this, one embodiment of the present invention further provides a nucleic acid molecule, a recombinant vector or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule encodes the first antibody and / or the second antibody as described above.
[0063] Nucleic acid molecules can be in the form of DNA (such as cDNA or genomic DNA or synthetic DNA) or RNA (such as mRNA or synthetic RNA). DNA can be single-stranded or double-stranded, and can also be a coding strand or a non-coding strand.
[0064] The sequence of the nucleic acid molecule can be derived from the antibody amino acid (AA) sequence by conventional means such as codon coding rules. The full-length sequence of the nucleic acid molecule or its fragments can usually be obtained by PCR amplification, recombination or artificial synthesis. The obtained nucleic acid molecule is inserted into an expression vector, then introduced into a host cell, and cultured under specific conditions to express the antibody.
[0065] The original vector for constructing the recombinant vector is various vectors conventional in the art, as long as it can hold the nucleic acid molecule. Typical vectors include plasmids (e.g., pBR322, pUC series, pET series pGEX series), viral vectors, bacteriophages (e.g., λgt4λB, λ-Charon, λΔz1, and M13), cosmids, and minichromosomes. The vector can be a cloning vector (i.e., used to transfer the nucleic acid molecule to a host and multiply in a host cell) or an expression vector (i.e., containing necessary genetic elements to allow the nucleic acid molecule inserted into the vector to be expressed in a host cell). The nucleic acid molecule of the present invention can be inserted into a suitable vector to form a cloning vector or an expression vector carrying the nucleic acid molecule.
[0066] The nucleic acid molecules encoding the antibodies FL and FH of the present invention can be inserted into two vectors, respectively, which can be introduced into the same or different host cells. When the heavy chain and the light chain are expressed in different host cells, each chain can be separated from the host cell expressing it, and the separated heavy chain and light chain are mixed and incubated under suitable conditions to form antibodies. In other embodiments, the nucleic acid molecules of antibodies FL and FH can also be cloned into a vector, and each nucleic acid sequence is connected to a suitable promoter downstream; for example, each nucleic acid sequence encoding the heavy chain and the light chain can be operably connected to different promoters, or the nucleic acid sequence encoding the heavy chain and the light chain can be operably connected to a single promoter, so that both the heavy chain and the light chain can be expressed by the same promoter. The choice of expression vector / promoter depends on the type of host cell used to produce the antibody.
[0067] The recombinant vector is transfected or transformed into the host cell using conventional techniques. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA are harvested after the exponential growth period and treated with CaCl2 or MgCl2; they can also be transfected by microinjection, electroporation or liposome packaging. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate coprecipitation, microinjection, electroporation, liposome packaging or particle bombardment to achieve gene introduction.
[0068] The host cell can be a prokaryotic or eukaryotic cell. Examples of prokaryotic host cells that can be used in the present invention include, but are not limited to, Escherichia coli (e.g., DH5α, JM109, BL21, W3110), Bacillus (e.g., Bacillus subtilis, Bacillus thuringiensis), and Enterobacteriaceae strains (e.g., Salmonella typhimurium, Serratia marcescens), and Pseudomonas. Examples of eukaryotic host cells that can be used for transformation include, but are not limited to, yeast, insect cells, and animal cells, such as Drosophila S2 or Sf9 cells, mammalian CHO, CHO DG44, CHO-S, COS-7, 293 series cells, HepG2, Huh7, 3T3, RIN, MDCK, and HEK293 cell lines. After obtaining a host cell transfected or transformed with a recombinant vector as described above, the antibody can be expressed by culturing under suitable conditions, and then separated to obtain a purified antibody.
[0069] In a preferred embodiment, the recombinant vector is a mammalian expression vector pBR322, and the host cell is a human kidney epithelial cell (293F cell).
[0070] The present invention is further described below in conjunction with specific examples. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as the conditions described in the Molecular Cloning Laboratory Guide (Fourth Edition) published by Cold Spring Harbor Laboratory, or usually under the conditions recommended by the manufacturer.
[0071] Example 1 Preparation of human MMP-9 rabbit monoclonal antibody
[0072] Based on the monoclonal antibody development technology of single B lymphocyte screening and culture, human matrix metalloproteinase 9 (MMP-9, from ABclonal, catalog number RP00103) was used as an immunogen to immunize New Zealand white rabbits; B lymphocytes were sorted from the rabbit spleen and cultured; RNA in antigen-specific B lymphocytes was extracted and reverse transcribed into cDNA; cDNA was amplified by PCR to obtain the genes of the heavy chain variable region (VH) and light chain variable region (VL) of the naturally paired rabbit monoclonal antibody; the aforementioned genes were loaded onto expression vectors containing the heavy chain constant region and the light chain constant region, and the vectors were transfected into host cells, the host cells were cultured, and the target antibodies 3F5 and 3G3 were isolated and purified.
[0073] The antibodies were sequenced by Jinkairui Biotechnology Co., Ltd. The amino acid (AA) sequences of the antibodies are shown in Tables 1-2. For ease of description, the light chain complementary determining regions CDR1-3 are represented by LCDR1-3, and the heavy chain complementary determining regions CDR1-3 are represented by HCDR1-3.
[0074] Table 1 Sequence information of rabbit monoclonal antibody 3F5 in this example
[0075]
[0076]
[0077] Table 2 Sequence information of rabbit monoclonal antibody 3G3 in this example
[0078]
[0079] In the above implementation, the specific steps include:
[0080] 1. Animal immunization: Each rabbit was immunized with 200 μg of antigen (from ABclonal, catalog number RP00103). Before the first immunization, the immunogen was mixed with an equal amount of complete Freund's adjuvant to prepare an emulsifier, which was injected subcutaneously at multiple points on the rabbit's abdomen and back; after the first immunization, 100 μg of the immunogen was mixed with an equal amount of incomplete Freund's adjuvant to prepare an emulsifier every 3 weeks, which was injected subcutaneously at multiple points on the rabbit's abdomen and back, and boosted twice; after three immunizations, rabbit serum samples were collected, and the titer against Human MMP-9 was determined by ELISA method. Rabbits with high serum titers were selected and boosted once with 200 μg of the immunogen injected subcutaneously at multiple points. Three days later, the animals were sacrificed and the spleen was taken.
[0081] 2. Isolate spleen cells: Take out a culture dish under aseptic operation in a safety cabinet, add 30-40 mL of basal culture medium (RPMI Medium 1640basic + 1% Pen Strep; RPMI 1640 purchased from Gibco, item number C11875500BT; PenStrep purchased from Gibco, item number 15140-163), put a cell sieve, take out the spleen and put it in the cell sieve, cut off the excess connective tissue and fat on the rabbit spleen tissue, cut the spleen tissue into pieces and put it into the cell sieve for grinding, take a clean grinding rod, and use the end of the pressing part to crush and grind the tissue to free the cells in the membrane. After passing through the cell sieve, they are suspended in the culture dish solution; wash the cell sieve with 10 mL of basal culture medium, and collect the basal culture medium outside the cell sieve. Centrifuge at 400g for 5min at room temperature, remove the supernatant, retain the cells, add 13mL of RBC lysis solution at room temperature (purchased from BioGems), gently blow away the cell clusters with a pipette and then time for 1min to lyse the red blood cells, add 37mL of basal culture medium and mix well to terminate the red blood cell lysis, centrifuge at 400g for 5min at room temperature, remove the supernatant, retain the cells, add 40mL of basal culture medium placed at room temperature, gently blow away the cell clusters with a pipette, resuspend the cells, complete the first wash, centrifuge at 400g for 5min at room temperature, remove the supernatant, retain the cells, add 20mL of basal culture medium placed at room temperature, gently blow away the cell clusters with a pipette, and resuspend the cells; filter the resuspended cells again through a cell sieve to remove the clumping cells, and then count the cells.
[0082] 3. Sorting B lymphocytes: Use conventional methods to separate B lymphocytes from the spleen and sort out antigen-specific B lymphocytes. For related methods, please refer to the patent "Method for efficiently separating single antigen-specific B lymphocytes from spleen cells (publication number: CN110016462A, publication date: 2019-07-16)" and the patent "A B lymphocyte in vitro culture system and application (publication number: CN111518765A, publication date: 2020-08-11)".
[0083] 4. Cloning of the gene encoding rabbit monoclonal antibody: The cultured B lymphocyte supernatant was used to identify positive clones by ELISA coated with MMP-9 antigen. The positive clone cells were collected and lysed and then analyzed by Quick-RNA TM RNA was extracted using a Micro Prep Kit (purchased from ZYMO, catalog number R1051) and reverse transcribed into cDNA. Using the aforementioned cDNA as a template, the naturally paired rabbit monoclonal antibody light chain variable region (VL) and heavy chain variable region (VH) were amplified from the cDNA of the corresponding positive clone using the PCR method and sequenced.
[0084] The PCR reaction system includes: 4 μL cDNA, 1 μL forward primer (10 mM), 1 μL reverse primer (10 mM), 12.5 μL 2×Gloria HiFi (from ABclonal, catalog number RK20717) and 6.5 μL H2O; the PCR amplification program includes: 98°C pre-denaturation for 30 s, followed by 40 cycles of 98°C for 10 s, 64°C for 30 s, and 72°C for 30 s, and finally kept at 72°C for 5 min, and the resulting reaction solution was stored at 4°C. The primer sequences (5'-3') for amplifying VL and VH genes are shown in Table 3, and F and R represent forward primers and reverse primers, respectively.
[0085] Table 3 Primer sequence information for amplifying rabbit monoclonal antibodies in this example
[0086] Primer name Sequence information VL-F tgaattcgagctcggtacccATGGACACGAGGGCCCCCAC (see SEQ ID NO. 21) VL-R cacacacacgatggtgactgTTCCAGTTGCCACCTGATCAG (see SEQ ID NO. 22) VH-F tgaattcgagctcggtacccATGGAGACTGGGCTGCGCTG (see SEQ ID NO. 23) VH-R gtagcctttgaccaggcagcCCAGGGTCACCGTGGAGCTG (see SEQ ID NO. 24)
[0087] 5. Production and purification of rabbit monoclonal antibodies: In order to obtain multiple rabbit monoclonal antibodies that recognize Human MMP-9, the mammalian expression vector pBR322 carrying the light chain constant region (CL) and heavy chain constant region (CH) genes was linearized with XbaI and NheI restriction endonucleases, respectively. The VL and VH genes containing the signal peptide amplified by the above PCR were purified and then constructed into the above expression vectors by homologous recombination to obtain light chain gene and heavy chain gene expression vectors. The successful construction of the expression vectors was verified by sequencing.
[0088] The expression profiles of the vectors used above are shown in Figure 1 , pBR322 origin and f1 origin are replication promoters, Ampcillin is a resistance gene, CMV promoter is a transcription promoter, SV40 PAterminator is a tailing signal, Light chain constant is the nucleic acid sequence of the light chain constant region (left), Heavy chain constant is the nucleic acid sequence of the heavy chain constant region (right). CL and CH genes were obtained by searching the IMGT online database (www.imgt.org) to obtain CH from rabbit IgGgamma C reign, and CL from rabbit IgG Kappa C reign.
[0089] The signal peptide of this embodiment can adopt the antibody expression signal peptide sequence commonly used in the art, such as the patent "Rabbit monoclonal antibody against human interferon α2 and its application (publication number: CN116063487A, publication date: 2023-05-05)" and the patent "High-affinity Human IL-5 rabbit monoclonal antibody and its application (publication number: CN115819578A, publication date: 2023-03-21)" The light chain variable region upstream has a signal peptide "MDTRAPTQLLGLLLLWLPGATF" or "MDTRAPTQLLGLLLLWLPGARC", and the heavy chain variable region upstream has a signal peptide "METGLRWLLLVAVLKGVQC".
[0090] The expression vectors containing the light chain gene and the heavy chain gene were transfected into 293F cells together. After transfection, the cells were cultured for 72-96 hours to obtain the culture supernatant containing the recombinant rabbit monoclonal antibody that recognizes Human MMP-9. Protein A affinity gel resin (purchased from Tiandi Renhe, catalog number SA023100) was used to purify the target antibody from the culture supernatant. The purified antibody was aliquoted and stored at -20°C for later use.
[0091] Example 2 Affinity determination of rabbit monoclonal antibodies 3F5 and 3G3
[0092] The antibody affinity was identified by ProbeLife's Gator Biomolecular Interaction Analyzer (Gator Prime device), using a Protein A probe. The test antibodies 3F5 and 3G3 were immobilized on the Protein A probe, with 3F5 immobilization concentration of 8.72 μg / mL and 3G3 immobilization concentration of 10.1 μg / mL; then the two antibodies were debinded with recombinant Human MMP-9 at two concentrations of 75 nM and 150 nM, respectively, to obtain affinity curves.
[0093] The affinity curves of antibodies 3F5 and 3G3 binding to human MMP-9 are shown in Figure 2-3 , where the ordinate represents the change in the thickness of the conjugate after the probe binds to the antibody and protein, the abscissa represents the binding time, the dark gray curve is the real-time binding value curve, and the light gray curve is the fitted average curve. The affinity constants calculated by curve fitting are shown in Table 4.
[0094] Table 4 Affinity-related parameter determination results of rabbit monoclonal antibodies
[0095] Antibody <![CDATA[K off (1 / s)]]> <![CDATA[K on (1 / Ms)]]> <![CDATA[K D (M)]]> 3F5 <![CDATA[1.37×10 -4 ]]> <![CDATA[3.16×10 5 ]]> <![CDATA[4.32×10 -10 ]]> 3G3 <![CDATA[2.94×10 -4 ]]> <![CDATA[3.28×10 5 ]]> <![CDATA[8.97×10 -10 ]]>
[0096] The results showed that the dissociation rate constants of antibodies 3F5 and 3G3 against human matrix metalloproteinase 9 were 1.37×10 -4, 2.94×10 -4 ; The binding rate constants were 3.16×10 5 , 3.28×10 5 ; The dissociation equilibrium constant is 4.32×10 -10 , 8.97×10 -10 , showing that the antibody has a high affinity for human MMP-9.
[0097] Example 3 Establishment of a double antibody sandwich ELISA based on antibodies 3F5 and 3G3 and its sensitivity determination
[0098] Detection antibody 3G3 biotin labeling: Take 100μg antibody 3G3, add 10μg biotin (purchased from Biosai Biotechnology, product number B5064), mix thoroughly after adding, incubate at 4℃ overnight, and set aside.
[0099] The double antibody sandwich enzyme-linked immunosorbent assay (ELISA) method was established using antibody 3F5 as the capture antibody and biotin-labeled antibody 3G3 as the detection antibody. The steps are as follows:
[0100] 1) Coating capture antibody 3F5: dilute antibody 3F5 to 2 μg / mL with 1×PBS, mix on a vortexer, add 100 μL / well to a 96-well microplate, cover with a cover film, and incubate in a 4°C refrigerator for 16-20 hours;
[0101] 2) Washing: After incubation, discard the liquid in the wells, wash the plate once with 1×PBST, add 300 μL of sample, let stand for 40 seconds, then discard the liquid in the wells and pat dry on flat paper;
[0102] 3) Blocking: Add 200 μL / well of blocking solution (1×PBS containing 2% BSA, 5% sucrose, 0.05% Tween 20 and 0.1% proclin 300, pH 7.2) into the plate wells, cover with cover film, and block at 37°C for 2 h. After blocking, discard the blocking solution, pat the ELISA plate dry, place it in a 37°C oven to dry for 0.5-2 h, and take it out for use;
[0103] 4) Adding antigen protein: Human MMP-9 protein (purchased from RD, product number DY911, component number 841030) was diluted with blocking solution (1×PBS containing 2% BSA, 0.05% Tween 20 and 0.1% proclin 300, pH 7.2) to the following concentrations: 2000, 1000, 500, 250, 125, 62.5, 31.25 and 0 pg / mL. Then, different concentrations were added to the ELISA plate in sequence at 100 μL / well, covered with a cover film, and incubated at 37°C for 2 h;
[0104] 5) Wash the plate: same as step 2);
[0105] 6) Add detection antibody 3G3: dilute the biotin-labeled antibody 3G3 (3G3-biotin) to 0.25 μg / mL, add 100 μL / well to the ELISA plate, cover with a cover film, and incubate at 37°C for 1 hour;
[0106] 7) Washing the plate: same as step 2);
[0107] 8) Add SA-HRP: dilute 100×SA-HRP (horseradish peroxidase labeled streptavidin, purchased from Wuhan Sanying Biotechnology Co., Ltd., catalog number SA00001-0) concentrate 100 times, add 100 μL / well to the ELISA plate, cover with cover film, and incubate at 37°C for 0.5 h;
[0108] 9) Washing the plate: same as step 2);
[0109] 10) Add color developing solution: Add 3,3',5,5'-tetramethylbenzidine (TMB) color developing solution (purchased from Tetramethylbenzidine, catalog number 4ATMB1000) to the ELISA plate at 100 μL / well, cover with cover film, and incubate at 37°C for 15 min;
[0110] 11) Reading: After incubation, remove the ELISA plate, add 50 μL of stop solution (1 mol / L hydrochloric acid) to each well, and immediately read the plate at 450 nm using an ELISA reader.
[0111] The concentration of human MMP-9 is taken as the horizontal axis, and the absorbance value OD 450nm Plot as the ordinate to obtain the standard curve (see Figure 4 ), showing good linearity, and the detection of human MMP-9 has good accuracy. The average value of the absorbance of 16 blank wells (dilution replacing antibody solution) and the sum of 2 times the standard deviation are taken as the absorbance value of sensitivity. The concentration obtained by substituting the absorbance value into the standard curve is the sensitivity of the double antibody sandwich enzyme-linked immunosorbent assay for detecting human MMP-9. The sensitivity of the antibody pair is 11.53 pg / mL. The results are shown in Table 5.
[0112] Table 5 Sensitivity test data of double antibody sandwich ELISA based on antibodies 3F5 and 3G3
[0113]
[0114] Example 4 Cross-reaction test of double antibody sandwich ELISA system based on antibodies 3F5 and 3G3
[0115] A variety of proteins similar to Human MMP-9 (purchased from RD, item number DY911, component number 841030) were used for cross-reaction to determine the antigen recognition specificity of the double antibody sandwich ELISA detection system. The cross-reaction test proteins are: Human NGAL / Lipocalin-2 (from ABclonal, item number RP01823), Human MMP-2 (purchased from RD, item number DY902, component number 843029), Human MMP-3 (from ABclonal, item number RP00220) and Human TIMP-4 (purchased from RD, item number 974-TSF-010). The double antibody sandwich ELISA method in the above Example 3 was used for detection, and the concentration of the standard protein was 2000pg / mL. The results are shown in Figure 5 , in the figure, Positive Control represents Human MMP-9.
[0116] like Figure 5 As shown, when the rabbit monoclonal antibodies 3F5 and 3G3 of the present invention were used to perform double antibody sandwich ELISA detection on multiple proteins, the reaction system only bound to Human MMP-9 and did not produce any cross reaction with other proteins; this indicates that the antibodies 3F5 and 3G3 have high specificity for Human MMP-9 protein.
[0117] Example 5 Thermal stability test of double antibody sandwich ELISA system based on antibodies 3F5 and 3G3
[0118] The ELISA plate coated with the capture antibody 3F5, the freeze-dried human MMP-9 protein, and the 100× concentrated detection antibody 3G3 were sealed and stored at -20°C and 37°C for 7 days, respectively, and then taken out and tested according to the double antibody sandwich ELISA method in Example 3. The coefficient of variation of the standard curves established under different treatment conditions was compared, and the thermal stability of the detection system constructed by antibodies 3F5 and 3G3 was analyzed. The results are shown in Tables 6 and Figure 6 .
[0119] Table 6 Stability test data of double antibody sandwich ELISA based on antibodies 3F5 and 3G3
[0120]
[0121] The results showed that the coefficient of variation of the concentration of Human MMP-9 protein detected by antibodies 3F5 and 3G3 treated at -20°C and 37°C, respectively, was less than 10%, indicating that the thermal stability of the detection system of the present invention was relatively strong.
[0122] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. An anti-human matrix metalloproteinase 9 antibody, characterized in that: is a first antibody or a second antibody, wherein: The amino acid sequences of CDR1, CDR2 and CDR3 in the light chain variable region of the first antibody are shown in SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 in the heavy chain variable region are shown in SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively; The amino acid sequences of CDR1, CDR2 and CDR3 in the light chain variable region of the second antibody are shown as SEQ ID NO.13, SEQ ID NO.14 and SEQ ID NO.15, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 in the heavy chain variable region are shown as SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.20, respectively.
2. The anti-human matrix metalloproteinase-9 antibody according to claim 1, characterized in that: The amino acid sequence of the light chain variable region of the first antibody is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.7; The amino acid sequence of the light chain variable region of the second antibody is shown in SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.
17.
3. The anti-human matrix metalloproteinase-9 antibody according to claim 2, characterized in that: The amino acid sequence of the light chain of the first antibody is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.6; The amino acid sequence of the light chain of the second antibody is shown in SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.
16.
4. The anti-human matrix metalloproteinase-9 antibody according to claim 1, characterized in that: The first antibody and / or the second antibody is a full-length antibody or an antigen-binding region of the full-length antibody; The antigen binding region is selected from Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv or sc(Fv)2.
5. An anti-human matrix metalloproteinase 9 antibody pair, characterized in that: The method comprises the first antibody and the second antibody as described in any one of claims 1 to 4.
6. Use of the anti-human matrix metalloproteinase-9 antibody according to any one of claims 1 to 4 or the anti-human matrix metalloproteinase-9 antibody pair according to claim 5 in the preparation of a human matrix metalloproteinase-9 detection kit.
7. A human matrix metalloproteinase 9 detection kit, characterized in that: It comprises the anti-human matrix metalloproteinase-9 antibody according to any one of claims 1 to 4 or the anti-human matrix metalloproteinase-9 antibody pair according to claim 5.
8. The human matrix metalloproteinase 9 detection kit according to claim 7, characterized in that: The detection kit is an enzyme-linked immunosorbent assay kit, an enzyme-linked immunospot assay kit, an immunohistochemistry kit, an immunofluorescence assay kit, an immunoblotting kit or a flow cytometry kit.
9. The human matrix metalloproteinase 9 detection kit according to claim 8, characterized in that: The detection kit is a double antibody sandwich enzyme-linked immunosorbent assay kit, comprising a first antibody and a second antibody, wherein the first antibody is used as a capture antibody, the second antibody is used as a detection antibody, and the second antibody is connected to a detection label.
10. A nucleic acid molecule, a recombinant vector comprising the nucleic acid molecule or a host cell comprising the nucleic acid molecule, characterized in that: The nucleic acid molecule encodes the anti-human matrix metalloproteinase-9 antibody according to any one of claims 1 to 4.
Citation Information
Patent Citations
Antibodies to matrix metalloproteinase 9
US20120135004A1
Antibodies to matrix metalloproteinase 9
US20130224210A1
Antibodies to matrix metalloproteinase 9 and methods of use thereof
US20150239988A1
MMP-9 antibodies and methods of use thereof
US20230074615A1
Antibodies specific for MMP9
WO2016023972A1
Cited By
Anti-human MMP-9 antibody and detection kit thereof
CN119978132A
Antibody for detecting total antibody concentration in blood and kit and application thereof
CN121991235A
An antibody for detecting total antibody concentration in blood, and a kit and use thereof
CN121991235B
